Shares of CureVac N.V. (CVAC) are rising more than 14% Friday morning after the company announced positive preliminary data from the early-stage studies of COVID-19 and Flu vaccine candidates.
Results from the Phase 1 study showed that the company’s Covid-19 vaccine candidate CV0501, successfully boosted antibody titers against BA.1 and the wild type variants, and was generally well tolerated across all tested dose groups.
Flu vaccine candidate Flu-SV-mRNA successfully boosted antibody titers against matching flu strain, even at lowest dose, the company said.
CureVac plans to advance these vaccine candidates to the next stage of study in this year.
CVAC is at $7.29 currently. It has traded in the range of $5.63-$31.84 in the last 1 year.
Source: Read Full Article
-
BTC: Jimmy Song Goes to El Salvador To Teach $4,000 Two-Day Bitcoin Programming Course
-
Anthony Pompliano Talks Bitcoin's Latest Surge and ETF Status
-
Bitcoin (BTC) Supply on Exchanges Drops to 6-Year Low as Tether Whales Eye Market Entry
-
Bitcoin's $28,000 Hurdle Sparks Red Monday for Cryptocurrencies
-
Roblox Slips 8% As Quarterly Results Fall Shy Of Estimates